期刊文献+

替米沙坦联合硝苯地平控释片对肥胖性高血压患者的疗效观察 被引量:6

Efficacy of Telmisartan combined with Nifedipine in patients with obesity hypertension
下载PDF
导出
摘要 目的观察替米沙坦联合硝苯地平控释片对肥胖性高血压患者的疗效及对患者血脂和胰岛素抵抗的影响。方法选取2010年6月~2011年6月就诊的肥胖性高血压患者190例,随机分为观察组和对照组,两组各95例。对照组予以硝苯地平治疗,观察组在对照组基础上予以替米沙坦治疗。观察两组的疗效、血脂、体重指数(BMI)、空腹血糖(FPG)、空腹胰岛素(FIns)和稳态胰岛素评价指数(HOMA-IR)。结果观察组总有效率为92.63%,对照组总有效率为81.05%,观察组总有效率优于对照组,差异有统计学意义(χ2=4.606,P=0.032)。治疗后,观察组的TC、TG、BMI和HOMA-IR较治疗前和对照组明显降低,差异有统计学意义(P<0.05或P<0.01)。两组治疗前后的LDL-C、HDL-CFPG和FIns水平差异无统计学意义(P>0.05)。结论替米沙坦联合硝苯地平控释片对肥胖性高血压疗效显著,有降低血脂水平、改善胰岛素抵抗的作用。 Objective To observe the efficacy of Telmisartan combined with Nifedipine in patients with obesity hypertension and its effect on blood lipids and insulin resistance.Methods 190 obese patients with hypertension from June 2010 to June 2011 were randomly divided into observation group and control group,each group was 95 cases.Control group were given Nifedipine,Telmisartan were perfermed on the basis of the control group in observation group.The effect,blood lipids,body mass index(BMI),fasting plasma glucose(FPG),fasting insulin(FIns) and insulin homeostasis assessment index(HOMA-IR) were observed in each group.Results The total effective rate was 92.63% in the observation group,81.05% in the control group,the difference was statistically significant(χ2 = 4.606,P = 0.032).After treatment,The levels of TC,TG,BMI and HOMA-IR in the observation group were significantly lower than those before treatment and the control group,the differences were statistically significant(P 〈0.05 or P 〈0.01).The levels of LDL-C,HDL-CFPG and FIns before treatment were not statistically different compared with after treatment(P 〈0.05).Conclusion The effect of Telmisartan combined with Nifedipine on blood pressure is very obvious,can decrease the blood lipid and improve the insulin resistance.
作者 吴池
出处 《中国医药导报》 CAS 2012年第21期80-81,84,共3页 China Medical Herald
关键词 原发性高血压 肥胖 血脂 替米沙坦 硝苯地平控释片 Hypertension Obesity Lipids Telmisartan Nifedipine
  • 相关文献

参考文献8

  • 1Trovato GM,Pirri C,Martines GF,et al. Lifestyle interventions,insulinresistance,and renal artery stiffness in essential hypertension [J]. ClinExp Hypertens,2010,32(5):262-269.
  • 2Gluszek J, Jankowska K. Is there relationship between the A1166Cpolymorphism of the angiotensin II receptor ATI and plasma renin activity,insulin resistance and reduction of blood pressure after angiotensin -converting enzyme inhibitor therapy [J]. Pol Arch Med Wewn,2008,118(4):194-200.
  • 3Madrigal L, Brady J, Raxter M, et al. Obesity,hypertension,and migration :a meta-analysis of populations of the South Asian diaspora [J]. Hum Biol,2011,83(l):71-86.
  • 4Galie N, Manes A, Negro L,et al. A raeta -analysis of randomizedcontrolled trials in pulmonary arterial hypertension [J], Eur Heart J,2009,30(4):394-403.
  • 5Derosa G, Maffioli P. Nifedipine and telmisartan for the treatment ofhypertension :the TALENT study [J]. Expert Rev Cardiovasc Ther,2011,9(12):1499-1503.
  • 6Aalbers J. Improving hypertension control in patients at cardiovascularrisk:the case for telmisartan-based therapy [J]. Cardiovasc J Afr,2011,22(1):45-46.
  • 7Marketou ME,Kontaraki JE,Tsakountakis NA,et al. Differential effectof telmisartan and amlodipine on monocyte chemoattractant protein-1and peroxisome proliferator -activated receptor -gamma gene expressionin peripheral monocytes in patients with essential hypertension [J]. Am JCardiol,2011,107(1):59-63.
  • 8Schneider F,Vossler S.Franke S,et al. Impact of insulin sensitivitytreatment with pioglitazone on endothelial function in non -diabeticpatients with arterial hypertension [J]. Int J Clin Pharmacol Ther,2009,47(5):311-320.

同被引文献40

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部